Back to top
more

Silence Therapeutics (SLN)

(Delayed Data from NSDQ)

$21.61 USD

21.61
125,885

-0.02 (-0.07%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $21.57 -0.04 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SLN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Silence Therapeutics PLC Sponsored ADR [SLN]

Reports for Purchase

Showing records 1 - 20 ( 28 total )

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 1

03/15/2024

Company Report

Pages: 8

Zerlasiran Shines in Phase 2 in Lp(a); Expect Phase 3 Program to Start in 2H24; 4Q23 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 2

03/13/2024

Daily Note

Pages: 4

Longer-Term Zerlasiran Phase 2 Data Support Advancement to Phase 3 Trial in CVD in 2H24; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 3

02/22/2024

Company Report

Pages: 9

Key Takeaways From Biotech Breakthroughs Lp(a) Event

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 4

01/18/2024

Company Report

Pages: 7

Underappreciated RNAi Platform Nearing Two Key Readouts Including in Potential Blockbuster Lp(a) Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 5

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for SLN 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 6

11/17/2023

Company Report

Pages: 9

3Q23 Results; Potential Blockbuster Lp(a) Program Progressing; Thalassemia Program Dropped; PT Down to $75; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 7

11/01/2023

Daily Note

Pages: 3

APOLLO Delivers Knockout Punch to Lp(a) in Multiple Dose Component; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 8

09/19/2023

Industry Report

Pages: 14

Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 9

08/17/2023

Company Report

Pages: 10

2Q23 Results; Nearing Multiple Data Readouts on Lead RNAi Programs in 4Q23 and Mid-2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 10

05/18/2023

Company Report

Pages: 9

1Q23 Results; Multiple Pipeline Data Readouts Anticipated in 4Q23; Lp(a) Phase 2 Program Topline Data Expected Mid-2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 11

05/11/2023

Company Report

Pages: 9

Management Meeting Highlights Focus on Lead Phase 2 RNAi Compounds Ahead of Next Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 12

03/17/2023

Company Report

Pages: 9

4Q22 Results; 2023 Could Hold Key Clinical Progress For Lead Compounds; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 13

12/06/2022

Company Report

Pages: 9

Lead Programs Progressing to Phase 2; Updating SLN360 Assumptions Following Olpasiran Transaction; Lowering PT to $80

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 14

09/26/2022

Industry Report

Pages: 48

Biotechnology - Ever Evolving Genetic Medicines

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 15

05/19/2022

Company Report

Pages: 8

Lead Compounds SLN360 and SLN124 to Shine in 2H22 With Data Readouts and Study Starts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 16

04/04/2022

Daily Note

Pages: 4

ACC Highlights Positive Attributes of SLN360 Including Dose-Dependent Lowering of Lp(a); Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 17

03/22/2022

Company Report

Pages: 9

4Q21 Results; Multiple Potential Catalysts to Further Validate RNAi Platform; Price Target to $95 as MDS Is Discontinued

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 18

02/09/2022

Daily Note

Pages: 4

Potential Blockbuster CVD Program SLN360 Generates Compelling Phase 1 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 19

12/13/2021

Daily Note

Pages: 3

Positive Update at ASH; SLN124 Could Have Pipeline-in-a-Pipeline Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Silence Therapeutics PLC Sponsored ADR

Industry: Medical - Drugs

Record: 20

11/23/2021

Company Report

Pages: 9

Positive Data on SLN124 Expected at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party